ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-13-1033
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Protein-Intrinsic and Signaling Network-Based Sources of Resistance to EGFR- And ErbB Family-Targeted Therapies in Head and Neck Cancer

Drug Resistance Updates
Cancer ResearchOncologyInfectious DiseasesPharmacology
2011English

Dual Blockade of EGFR and C-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells

Clinical Cancer Research
Cancer ResearchOncology
2011English

EGFR and HER2 Signaling in Breast Cancer Brain Metastasis

Frontiers in Bioscience - Elite
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2016English

Lymphotoxin-Β Interacts With Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity Against Breast Cancer Models Resistant to Anti-Her2 Drugs

PLoS ONE
Multidisciplinary
2015English

HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Detection of EGFR- And HER2-activating Mutations in Squamous Cell Carcinoma Involving the Head and Neck

Modern Pathology
Forensic MedicinePathology
2006English

Therapy Resistance in Head and Neck Cancer Stem Cells

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

EGFR and Prion Protein Promote Signaling via FOXO3a-KLF5 Resulting in Clinical Resistance to Platinum Agents in Colorectal Cancer

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy